Specialty ingredients solutions provider Barentz has entered into exclusive discussions to acquire 100% equity of Fengli Group, a specialty chemicals distributor for pharmaceutical excipients and active ingredients in China.
Established in 1996 and headquartered in Beijing, Fengli sources pharma excipients and active ingredients from 35 international principals and serves more than 2,000 customers in pharmaceutical production, research and development. The company’s primary focus is on the pharma and health product markets in mainland China. Their facilities include an analytical pharma lab for product formulation and support, as well as excipient research, development, and application labs.
The strategic move will grant Barentz access to the Chinese pharma market and establish a robust sales network centered around innovative excipients and active pharma ingredients (APIs). The partnership would further enhance the service and commercial capabilities of Barentz in China while enabling Fengli Group to expand its international presence.
Parties expect to complete the acquisition during the second half of 2025, with completion subject to customary closing conditions and regulatory clearances.